The CUSA Clarity Bone Tip Study
Launched by INTEGRA LIFESCIENCES CORPORATION · Mar 6, 2020
Trial Information
Current as of August 28, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject is at least 18 years of age
- • Subject requires a cranial skull base procedure involving removal of bone with ultrasonic aspirator
- • Subject is an appropriate candidate to receive use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery, per the study surgeon
- • Subject signed the IRB/EC-approved informed consent form demonstrating that the subject is willing and able to participate in this clinical study and to comply with all study procedures
- Exclusion Criteria:
- • Subject is currently pregnant or plans to become pregnant prior to the study index surgery
- • Subject has any significant medical condition that in the opinion of the investigator will interfere with protocol evaluation and participation
- • Subject's surgical plan includes utilizing CUSA Clarity Bone Tip for bone removal anywhere besides the cranial skull base in an open craniotomy (e.g. transsphenoidal approach or spinal procedures).
- • Subject is a prisoner or member of a different vulnerable population that should not be included in the study per the investigator or ethics committee.
- Intra-operative exclusion criteria :
- • Surgeon does not utilize CUSA Clarity Bone Tip for cranial skull base bone removal during surgery or utilizes CUSA Clarity Bone Tip anywhere else besides the cranial skull base
About Integra Lifesciences Corporation
Integra LifeSciences Corporation is a leading global medical technology company specializing in regenerative medicine and neurosurgery. With a commitment to innovation and excellence, Integra develops a diverse range of advanced technologies and products designed to improve patient outcomes in areas such as tissue regeneration, surgical reconstruction, and advanced wound care. The company is dedicated to supporting healthcare professionals through clinical trials that aim to validate the safety and efficacy of its cutting-edge solutions, ultimately enhancing the quality of care for patients worldwide. Integra’s focus on research and development, coupled with its robust portfolio, positions it as a key player in the medical device industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Udine, , Italy
Treviso, , Italy
Hamm, , Germany
Münster, , Germany
Athens, , Greece
Bari, , Italy
Patients applied
Trial Officials
Jason Marzuola
Study Director
Integra LifeSciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials